ATE526041T1 - Verfahren zur hemmung okularer vorgänge - Google Patents

Verfahren zur hemmung okularer vorgänge

Info

Publication number
ATE526041T1
ATE526041T1 AT02804786T AT02804786T ATE526041T1 AT E526041 T1 ATE526041 T1 AT E526041T1 AT 02804786 T AT02804786 T AT 02804786T AT 02804786 T AT02804786 T AT 02804786T AT E526041 T1 ATE526041 T1 AT E526041T1
Authority
AT
Austria
Prior art keywords
inhibiting
methods
occular
processes
agents
Prior art date
Application number
AT02804786T
Other languages
English (en)
Inventor
David Hinton
Shikun He
Noelynn Oliver
Original Assignee
Fibrogen Inc
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc, Univ Southern California filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE526041T1 publication Critical patent/ATE526041T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Surgery (AREA)
AT02804786T 2001-12-11 2002-12-11 Verfahren zur hemmung okularer vorgänge ATE526041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33954701P 2001-12-11 2001-12-11
PCT/US2002/039777 WO2003049773A1 (en) 2001-12-11 2002-12-11 Methods for inhibiting ocular processes

Publications (1)

Publication Number Publication Date
ATE526041T1 true ATE526041T1 (de) 2011-10-15

Family

ID=23329537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804786T ATE526041T1 (de) 2001-12-11 2002-12-11 Verfahren zur hemmung okularer vorgänge

Country Status (7)

Country Link
US (1) US20030153524A1 (de)
EP (1) EP1463531B1 (de)
JP (1) JP2005519881A (de)
CN (1) CN1602207A (de)
AT (1) ATE526041T1 (de)
AU (1) AU2002366641A1 (de)
WO (1) WO2003049773A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351407B2 (en) * 2002-04-30 2008-04-01 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US20040116409A1 (en) * 2002-11-08 2004-06-17 Campochiaro Peter A Ocular therapy
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2929782A1 (de) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Verbesserte modalitäten zur behandlung von degenerativen erkrankungen der netzhaut
CN101884789A (zh) * 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
WO2006099353A1 (en) * 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
CA2606778A1 (en) 2005-05-05 2006-11-16 Fibrogen, Inc. Vascular disease therapies
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP2862867A3 (de) * 2005-10-25 2015-08-05 The Johns Hopkins University Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2342340A1 (de) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna-interferenz bei hautindikationen
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2448971A1 (de) * 2009-07-02 2012-05-09 Fibrogen, Inc. Verfahren zur behandlung von muskeldystrophie
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
KR101063524B1 (ko) 2010-02-08 2011-09-07 한림대학교 산학협력단 검정옥수수 추출물을 함유하는 당뇨합병성 신장섬유증 억제용 조성물
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
EP3560503B1 (de) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna-interferenz bei dermalen und fibrotischen erkrankungen
TR201902542T4 (tr) * 2010-04-13 2019-03-21 M Lab Gmbh Glokom i̇çi̇n tani yöntemleri̇
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
JP6106883B2 (ja) * 2012-08-27 2017-04-05 学校法人福岡大学 第二次高調波光を用いた新規コラーゲン線維化評価モデル
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
JP2017514908A (ja) * 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
CN104745587B (zh) * 2015-01-05 2017-07-21 西安交通大学医学院第一附属医院 用于识别结缔组织生长因子的核酸适配子及其应用
TWI640308B (zh) * 2017-03-29 2018-11-11 林伯剛 Device for stimulating optic nerve fibers
TWI674124B (zh) * 2017-09-30 2019-10-11 三凡生技研發股份有限公司 促進眼睛保健之胜肽及其組合物
CN109706238B (zh) * 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
IL283127B1 (en) 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
EP4161527A4 (de) * 2020-06-05 2024-06-26 OccuRx Pty Ltd Verbindungen und verfahren zur behandlung von augenerkrankungen
WO2023196555A1 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for ocular fibrosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US7026299B2 (en) * 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
ATE405651T1 (de) * 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
CN1170849C (zh) * 1998-12-14 2004-10-13 迈阿密大学 结缔组织生长因子片段及其方法和用途
AU6929500A (en) * 1999-08-27 2001-03-26 Fibrogen, Inc. Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
EP1311277A4 (de) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methoden zur fibrose-modulation
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor

Also Published As

Publication number Publication date
WO2003049773A1 (en) 2003-06-19
CN1602207A (zh) 2005-03-30
AU2002366641A1 (en) 2003-06-23
EP1463531B1 (de) 2011-09-28
HK1069767A1 (en) 2005-06-03
US20030153524A1 (en) 2003-08-14
EP1463531A4 (de) 2005-09-07
EP1463531A1 (de) 2004-10-06
JP2005519881A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
WO2003055443A3 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE424560T1 (de) Marker für neuromyelitis optica
ATE435012T1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
DE602004010267D1 (de) Zusammensetzung mit mindestens einem substituiertem 2- 2-(4-aminophenyl)ethenyl -1-pyridinium-derivat, verfahren zur behandlung von keratinfasern damit, vorrichtung und verwendung
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
WO2003039491A3 (en) Novel isoforms of vascular endothelial cell growth inhibitor
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
ATE505192T1 (de) Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69902975D1 (de) Endbearbeitungswerkzeug, insbesondere für ophtalmische Linse, und Einrichtung zur Verwendung desselben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties